Carvedilol contraindications: Difference between revisions
Jump to navigation
Jump to search
| Line 11: | Line 11: | ||
:*[[Sick sinus syndrome]] | :*[[Sick sinus syndrome]] | ||
:*Severe [[bradycardia]] (unless a permanent pacemaker is in place). | :*Severe [[bradycardia]] (unless a permanent pacemaker is in place). | ||
:*[[Cardiogenic shock]] or who have [[ | :*[[Cardiogenic shock]] or who have decompensated [[heart failure]] requiring the use of intravenous [[inotropic]] therapy. Such patients should first be weaned from intravenous therapy before initiating COREG | ||
:*Severe hepatic impairment | :*Severe hepatic impairment | ||
:*Serious [[hypersensitivity]] reaction (e.g., [[Stevens-Johnson syndrome]], [[anaphylactic reaction]], [[angioedema]]) to any component of this medication or other medications containing carvedilol.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = |first = | title = COREG (CARVEDILOL) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | :*Serious [[hypersensitivity]] reaction (e.g., [[Stevens-Johnson syndrome]], [[anaphylactic reaction]], [[angioedema]]) to any component of this medication or other medications containing carvedilol.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = |first = | title = COREG (CARVEDILOL) TABLET, FILM COATED [GLAXOSMITHKLINE LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c57982f2-c7da-488a-7ea9-b9609439ac68#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | ||
Revision as of 20:26, 20 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
COREG is contraindicated in the following conditions:
- Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of COREG.
- AV block (Second- or third-degree)
- Sick sinus syndrome
- Severe bradycardia (unless a permanent pacemaker is in place).
- Cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating COREG
- Severe hepatic impairment
- Serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, anaphylactic reaction, angioedema) to any component of this medication or other medications containing carvedilol.[1]
References
Adapted from the FDA Package Insert.